EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Longitudinal and combined assessment of 24(S)-hydroxycholesterol and Neurofilament light chain in the early stages of Huntington's disease

Lidia Sarro, Marta Valenza, Alessia Mongelli, Alice Passoni, Anna Castaldo, Monica Favagrossa, Laura Pasetto, Valentina Bonetto, Renzo Bagnati, Marina Grisoli, Anna Nigri, Giulia Birolini und 8 weitere

Neurobiology of Disease · 2026-06 · 223 · 107381

DOI: 10.1016/j.nbd.2026.107381 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neurobiology of Disease, 2026-06. Verfasst von Lidia Sarro und 19 weiteren Autor:innen. Beteiligte Einrichtung: Fondazione IRCCS Istituto Neurologico Carlo Besta, via Celoria 11, 20133 Milan, Italy. Hauptthemen laut MEDLINE: Hydroxycholesterols, Neurofilament Proteins, Huntington Disease. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ministero della Salute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Huntington's Disease (HD) is an autosomal dominant neurodegenerative disorder. Recent clinical research has focused on neurofilament light chain protein (NfL), and cholesterol metabolites as potential fluid biomarkers related to disease progression. Our aim was to explore whether the combined longitudinal assessment of NfL and cholesterol-derived metabolites would improve the characterization of early HD stages. We enrolled 96 HD individuals and 63 healthy controls. Disease stage of HD participants was determined using both the system based on Total Motor Score (TMS), and the new HD-Integrated Staging System (HD-ISS). Concentrations of plasma NfL, and cholesterol precursors and metabolites, were measured at baseline and 2-year follow-up. In premanifest individuals, classified according to TMS, we found significantly reduced 24(S)-hydroxycholesterol (24S-OHC), a metabolite entirely derived from brain cholesterol catabolism, and normal level of NfL. When applying the HD-ISS, 24S-OHC was significantly reduced in HD-ISS-1 (25.6 ± 7.6 ng/ml) and HD-ISS-3 (30.5 ± 15.7) compared with controls (39.5 ± 14.1). NfL was increased in HD-ISS-1 (16.1 ± 6.5 pg/ml), HD-ISS-2 (16.1 ± 6.5) and HD-ISS-3 (27.0 ± 6.9) compared with controls (5.5 ± 1.7 pg/ml). In HD-ISS-0, all biomarker concentrations were similar to those of controls. At follow-up, NfL increased in HD-ISS-1 (+20%; p < 0.005). ROC analyses showed that NfL discriminated HD-ISS-0 and HD-ISS-1 from controls. 24S-OHC distinguished HD-ISS-1 from controls. Plasma NfL and 24S-OHC concentrations provide complementary insights into early biological changes in HD, and holds the potential to characterize the transition phase from the pre-symptomatic to the early symptomatic stage.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HydroxycholesterolsNeurofilament ProteinsHuntington DiseaseHumansFemaleMaleLongitudinal StudiesAdultBiomarkersMiddle AgedDisease Progression

Stichwörter der Autor:innen

Cholesterol metabolitesFluid biomarkerNfLOxysterol

Substanzen

HydroxycholesterolsNeurofilament Proteins24-hydroxycholesterolneurofilament protein LBiomarkers

Autor:innen und Institutionen

  • Fondazione IRCCS Istituto Neurologico Carlo Besta, via Celoria 11, 20133 Milan, Italy.
  • Department of Biosciences, University of Milan, via Celoria 26, 20133 Milan, Italy.
  • Istituto di Ricerche Farmacologiche Mario Negri IRCCS, via Mario Negri 2, 20156 Milan, Italy.
  • Unit of Neuroradiology, Fondazione IRCCS Istituto Neurologico Carlo Besta, via Celoria 11, 20133 Milan, Italy.
  • Department of Biosciences, University of Milan, via Celoria 26, 20133 Milan, Italy; Istituto Nazionale di Genetica Molecolare "Romeo ed Enrica Invernizzi", via F. Sforza 35, 20122 Milan, Italy.
  • Politecnico di Milano, Department of Electronics, Informatics, and Bioengineering, via Ponzio 34/5, 20133 Milan, Italy; Computational multi-Omics of Neurological Disorders (MIND) Lab, Fondazione IRCCS Istituto Neurologi…

Förderung

  • Ministero della Salute

Zitieren

APA

Sarro, L., Valenza, M., Mongelli, A., Passoni, A., Castaldo, A., Favagrossa, M., Pasetto, L., Bonetto, V., Bagnati, R., Grisoli, M., Nigri, A., Birolini, G., Zerbini, E., Tomè, S., Masseroli, M., Salvi, E., Colombo, L., Salmona, M., Cattaneo, E., & Mariotti, C. (2026). Longitudinal and combined assessment of 24(S)-hydroxycholesterol and Neurofilament light chain in the early stages of Huntington's disease. Neurobiology of Disease, 223, 107381. https://doi.org/10.1016/j.nbd.2026.107381

Vancouver

Sarro L, Valenza M, Mongelli A, Passoni A, Castaldo A, Favagrossa M, et al. Longitudinal and combined assessment of 24(S)-hydroxycholesterol and Neurofilament light chain in the early stages of Huntington's disease. Neurobiology of Disease. 2026;223:107381. doi:10.1016/j.nbd.2026.107381

BibTeX
@article{Sarro2026,
  author = {Sarro, Lidia and Valenza, Marta and Mongelli, Alessia and Passoni, Alice and Castaldo, Anna and Favagrossa, Monica and Pasetto, Laura and Bonetto, Valentina and Bagnati, Renzo and Grisoli, Marina and Nigri, Anna and Birolini, Giulia and Zerbini, Elena and Tomè, Simone and Masseroli, Marco and Salvi, Erika and Colombo, Laura and Salmona, Mario and Cattaneo, Elena and Mariotti, Caterina},
  title = {Longitudinal and combined assessment of 24(S)-hydroxycholesterol and Neurofilament light chain in the early stages of Huntington's disease},
  journal = {Neurobiology of Disease},
  year = {2026},
  volume = {223},
  pages = {107381},
  doi = {10.1016/j.nbd.2026.107381}
}
Kostenlos starten →